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Abstract
The attraction of leukocytes from circulation to inflamed lungs depends on the activation of both
the leukocytes and the resident cells within the lung. In this study we determined gene expression
and secretion patterns for monocyte chemoattractant protein-1 (MCP-1/CCL2) and T-cell specific
CXCR3 agonistic chemokines (Mig/CXCL9, IP-10/CXCL10, and I-TAC/CXCL11) in TNF-α-, IFN-
γ-, and IL-1β-stimulated human alveolar epithelial cells type II (AEC-II). AEC-II constitutively
expressed high level of CCL2 mRNA in vitro and in situ , and released CCL2 protein in vitro .
Treatment of AEC-II with proinflammatory cytokines up-regulated both CCL2 mRNA expression
and release of immunoreactive CCL2, whereas IFN-γ had no effect on CCL2 release. In contrast,
CXCR3 agonistic chemokines were not detected in freshly isolated AEC-II or in non-stimulated
epithelial like cell line A549. IFN-γ, alone or in combination with IL-1β and TNF-α resulted in an
increase in CXCL10, CXCL11, and CXCL9 mRNA expression and generation of CXCL10 protein
by AEC-II or A549 cells. CXCL10 gene expression and secretion were induced in dose-dependent
manner after cytokine-stimulation of AEC-II with an order of potency IFN-γ>>IL-1β ≥ TNF-α.
Additionally, we localized the CCL2 and CXCL10 mRNAs in human lung tissue explants by in situ
hybridization, and demonstrated the selective effects of cytokines and dexamethasone on CCL2
and CXCL10 expression. These data suggest that the regulation of the CCL2 and CXCL10
expression exhibit significant differences in their mechanisms, and also demonstrate that the
alveolar epithelium contributes to the cytokine milieu of the lung, with the ability to respond to
locally generated cytokines and to produce potent mediators of the local inflammatory response.
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Background
Many pulmonary disorders are characterized by accumu-
lation and activation of inflammatory cells within the
lung, followed by the release of regulatory mediators,
resulting in macrophage/lymphocyte alveolitis. Sarcoido-
sis, tuberculosis, hypersensitivity pneumonitis, eosi-
nophilic pneumonia, and usual interstitial pneumonia
represent such lung diseases that have in common the
selective recruitment and activation of different types of
leukocytes, and therefore, exhibit distinct forms of alveo-
litis [1-5]. The inflammatory phase of alveolitis is initiated
by epithelial and/or endothelial injury involving the
structures of the alveolar wall. The alveolar surface area of
the lung is covered with a layer of alveolar epithelial cells
type I and type II. Type I cells function as a physical bar-
rier, whereas type II cells produce surfactant and act as
progenitors to replace injured alveolar epithelial cells type
I [6]. Thus, located at the boundary between the alveolar
airspace and the interstitium, alveolar epithelial cells type
II (AEC-II) are ideally situated to regulate the recruitment
and activation of different types of leukocytes through the
production of chemokines/cytokines in response to
inflammatory stimulation from the alveolar space. Recent
studies have suggested that AEC-II secrete a variety of
mediators, including proinflammatory cytokines and
chemokines important for the recruitment of monocytes /
macrophages and T cells into the lung interstitium and
alveolar space [7-10].
Although leukocyte recruitment is a complex and multi-
step process with involvement of different types of cells,
cell-surface adhesion molecules, and soluble inflamma-
tory mediators, the prominent role of the attractant mole-
cules such as chemokines has widely been appreciated
[11,12]. Chemokines are a superfamily of small, secreted
proteins that direct the recruitment of leukocytes to the
sites of inflammation. They are classified into four sub-
families on the basis of the primary sequence of the first
two of four invariant cysteine residues, and named
according to the recommendation for new systematic
nomenclature for human chemokines [11]. CC chemok-
ines/CCL attract monocytes, eosinophils, basophils, den-
dritic and T cells and signal through chemokine receptors
CCR1 to CCR10. In contrast to CC chemokines, the CXC
chemokines (CXCL) are divided into two classes depend-
ing on the presence of the glutamate-leucine-arginine
motif (ELR) in the NH2-terminal domain. The CXC chem-
okines signal through the chemokine receptors CXCR1 to
CXCR5 (reviewed in [11]). The CC chemokine, monocyte
chemoattractant protein-1/CCL2 (CCL2), has been
shown in vitro and in vivo to target preferentially mono-
cytes and memory T cells through the CCR2 [13-16].
Monokine induced by IFN-γ (Mig/CXCL9), IFN-induced
protein of 10 kDa (IP-10/CXCL10), and IFN-inducible T-
cell α-chemoattractant (I-TAC/CXCL11) are all members
of the non-ELR CXCL class and target preferentially mem-
ory T cells and natural killer cells through the single and
shared receptor CXCR3 [17,18]. Recently, it has been
reported that some chemokine receptors are associated
with human Th1 or Th2 cells, and therefore the respective
agonists can selectively attract the respective Th cell subset
into inflammatory sites (reviewed in [12]).
In this context, we hypothesized that AEC-II are an impor-
tant source of CCL2 and the CXCR3 agonistic chemokines
in the lung, and through expression of these mediators
involved in the homing of immune effector cells during
lung inflammatory processes. As a model we investigated
the gene expression and production of chemokines,
important for the recruitment of CCR2 and CXCR3 bear-
ing mononuclear leukocytes, by human primary AEC-II
and airway epithelial like cell line A549 after exposure of
the cells to the proinflammatory cytokines TNF-α, IFN-γ,
and IL-1β. A striking result was the difference between
spontaneous and cytokine-induced CCL2, CXCL9,
CXCL10, and CXCL11 mRNA expression and/or protein
production in both human AEC-II and A549 cell cultures.
Finally, we provide evidence of selective CCL2 and
CXCL10 mRNA expression of human AEC-II in vivo .
Materials and Methods
Reagents
The following materials were purchased from GIBCO BRL
(Paisley, Scotland): PBS, RPMI 1640 medium with 2 mM
L-glutamine, FCS, HEPES, TRIZOL Reagent, SuperScript™
RNase H- reverse transcriptase (RT), oligo (dT)12–18 primer
and agarose; penicillin/streptomycin solution and
sodium pyruvate from Biochrom (Berlin, FRG); trypsin/
EDTA solution from Boehringer-Mannheim (Mannheim,
FRG); collagen R from Serva (Heidelberg, FRG); chloro-
form and isopropanol from Merck (Darmstadt, FRG);
recombinant human IFN-γ (specific activity 3 × 107 U/mg)
and recombinant human IL-1β (specific activity 2 × 108 U/
mg) from Biotrend (Cologne, FRG); recombinant human
TNF-α was a courtesy of Dr. E. Schlick (Knoll AG, Ludwig-
shafen, FRG); dexamethasone from Sigma (St. Louis,
MO); 100 mm plastic dishes, 75 cm2 tissue culture flask
and 24-well cell culture plates from NUNC (Wiesbaden,
FRG). All reagents used were of the highest available grade
and were dissolved in pyrogen-free water.
Human Lung Tissue
Lung tissue samples were obtained from subjects with
lung cancer undergoing lobectomy or pneumectomy.
Twelve patients with bronchogenic carcinoma, without
any other systemic or pulmonary diseases, were enrolled
in this study. All subjects were smokers and have had no
respiratory tract infection within the last month. None of
them was taking immunosuppressants within one month
before surgery. In addition, lung tissue samples wereRespiratory Research 2005, 6:75 http://respiratory-research.com/content/6/1/75
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obtained from 3 patients with pulmonary sarcoidosis who
had undergone diagnostic wedge biopsies and from 3
patients with pulmonary tuberculosis who had under-
gone upper lobectomy due to destructive tuberculoma.
Informed consents were obtained from all subjects. The
study was approved by the medical ethics committees of
the involved institutions.
Primary Human Alveolar Epithelial Cells Type II
Samples from macroscopically tumor-free lung tissue
were cut from the surgical specimens and used for cell iso-
lation procedure as described previously [19]. In brief, the
lung tissue was first sliced and slices were washed three
times at 4°C in PBS. The washed slices were incubated in
sterile dispase solution at 37°C for 45 min. After dispase
digestion the lung tissue slices were cut into small, pipeta-
ble pieces, and thoroughly pipetted for several min. Crude
tissue and cell suspensions were filtered through nylon
gauze with meshes of 100 µm, 50 µm, and 20 µm. The
resulting single cell suspension was placed on Ficoll sepa-
rating solution and centrifuged at 800 × g for 20 min. The
AEC-II-enriched cells from the interphase were incubated
in 100 mm plastic dishes at 37°C in humidified air con-
taining 5% CO2 for 15, 20 and 30 min with seeding of
non-adherent cells on fresh dishes for each time interval
to remove adherent cells (alveolar macrophages, mono-
cytes, fibroblasts, and endothelial cells). To remove
remaining monocytes/macrophages and lymphocytes,
antibodies against CD3 (OKT3, ECACC 86022706) and
CD14 (HB-246 ATCC) were added and the antibody-
binding cells were removed by anti-mouse IgG coated
magnetic beads and Magnetic Activated Cell Sorting
(MACS) system (Miltenyi Biotec, Bergisch Gladbach,
FRG) as suggested by the supplier. Identity of type II alve-
olar epithelial cells was confirmed by a modified Papani-
colaou staining, their alkaline phosphatase activity, and
SP-A mRNA expression in RT-PCR (see below). Cell purity
was assessed by immunoperoxidase staining with mono-
clonal antibodies directed against CD3 and CD14 (Immu-
notech, Marseille, France) as previously described [20].
Viability of the AEC-II after isolation was > 97% as deter-
mined by trypan blue exclusion. After the final step of
MACS purification, the AEC-II preparations included in
this report were free of CD14+ and CD3+ cells as deter-
mined by immunocytochemistry. 98 ± 1.3% of cells were
identified as AEC-II by the presence of dark blue inclu-
sions as revealed by modified Papanicolaou staining and
93 ± 2.1% of cells were positive for alkaline phosphatase
(data not shown). All RNA samples isolated from these
AEC-II preparations contained SP-A mRNA, and CD3 and
CD14 mRNA were found in four of twelve samples by RT-
PCR (data not shown). In order to avoid false positive
results from contaminated cells, these four AEC-II prepa-
rations were excluded from further experimental data
analysis.
A549 Cell Line
A549 cells were used as the positive control for CCL2,
CXCL9, CXCL10, and CXCL11 mRNA expression and pro-
tein production upon stimulation with proinflammatory
cytokines. Experiments were performed with cells after 7,
8 and 9 passages after thawing and inoculation in culture.
Cells were grown on 75 cm2 tissue culture flask in culture
medium (CM) (RPMI1640 medium, 10% heat inacti-
vated FCS, 1% penicillin/streptomycin solution, 1%
sodium pyruvate solution and 20 mM HEPES) in a
humidified atmosphere containing 5% CO2 at 37°C for 5
days. After this culture period, cells were removed from
plastic surfaces by treatment with trypsin/EDTA solution
(0.05/0.02% in PBS) for 10 min at 37°C, washed twice in
PBS and suspended in CM.
Cell Cultures
Immediately after purification, AEC-II were suspended in
CM (1 × 106 cells/ml) and treated with TNF-α (1 – 10 ng/
ml), IFN-γ (10 – 100 U/ml) or IL-1β (10 – 100 U/ml) in
collagen R-coated 24-well plates at 37°C, 5% CO2 atmos-
phere. A549 cells were plated at 1 × 106 /ml in 24-well
plates in the same culture condition as for AEC-II and
stimulated with TNF-α (1 – 10 ng/ml), IFN-γ (50 – 500 U/
ml) or IL-1β (50 – 500 U/ml) in different combinations as
indicated in the Results section. At the indicated time, cell-
free supernatants were harvested and stored at -70°C, and
cell pellets were extracted for total RNA. The cell viability
after culture always exceeded 95% in both AEC-II and
A549 cells as determined by trypan blue exclusion. For
samples of RNA from freshly isolated AEC-II or harvested
A549 cells, they were subjected to RNA isolation proce-
dures before cultures, henceforth referred to as non-cul-
tured controls.
Reverse Transcriptase Polymerase Chain Reaction (RT-
PCR)
Total RNA was extracted from cells using TRIzol according
to manufacturer's instructions (GIBCO BRL). Equal
amounts of total RNA from each sample were primed with
oligo dT and reverse-transcribed with SuperScript™ RT for
1 h at 37°C to produce complementary DNA (cDNA). The
resulting cDNAs (volume of 2.5 µL) were used for the
amplification by PCR of specific targets: CCL2, CXCL10,
CXCL11, CXCL9, SPA, and the housekeeping gene β-actin.
To demonstrate that RNA samples from AEC-II were not
contaminated by RNAs from other types of cells (lym-
phocytes or alveolar macrophages (AM)) CD3- and
CD14-specific primers were also used. All primers were
intron-spanning to avoid false positive results by contam-
ination with genomic DNA (Table 1). Target cDNA was
amplified using a three-step PCR and an automated ther-
mocycler (Biometra, Göttingen, FRG) according to Mur-
ray et al. [21] with primer pairs for CD3 and CD14, and as
previously described [19] with primer pairs for β-actin.Respiratory Research 2005, 6:75 http://respiratory-research.com/content/6/1/75
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PCR conditions for CCL2 amplification included: 95°C
for 5 min, 95°C for 30 s, 60°C for 30 s, 72°C for 1 min,
and 72°C (terminal extension) for 5 min; for CXCL10,
CXCL11, and CXCL9: 94°C for 1 min, 53°C for 1 min,
72°C for 2 min; and for SP-A: 94°C for 1 min, 54°C for 1
min, 72°C for 1 min 30 s, and 72°C (terminal extension)
for 15 min. The numbers of cycles were the same for all
targets (35 cycles), with the exception for SP-A (30 cycles).
PCR products (for predicted sizes see Table 1) were elec-
trophoresed on 1.5% agarose gels and stained with Gel-
Star® stain (FMC BioProducts, Rockland, ME). Gel analysis
was done densitometrically with "Gel Doc 2000" gel doc-
umentation system and "Quantity One 4.0.3" software
(Bio-Rad Laboratories, Hercules, CA). To ensure that RNA
was effectively reverse transcribed to cDNA for each con-
dition and that stimulation with cytokines by itself did
not have any effect on the housekeeping gene β-actin
expression, the β-actin PCR was routinely performed in
each experiment. To assure the identity of the PCR-ampli-
fied fragments, the size of each amplified mRNA fragment
was compared with DNA standards (100 bp DNA Ladder;
GIBCO BRL, Paisley, Scotland) electrophoresed on the
same gel. Additionally, the PCR products were sequenced
by the dideoxynucleotide chain-termination method with
an autosequencer (ABI PRISM-377, Perkin-Elmer), and
their specificity was further confirmed by comparing with
the sequence data from the GenBank http://
www.ncbi.nlm.nih.gov/Genebank/ database (accession
numbers M68519 for SP-A, X14768 for CCL2, AF030514
for CXCL11, NM002416 for CXCL9, and NM001565 for
CXCL10) (data not shown). Results are expressed as per-
cent of signal intensities assigned to the target mRNA of
the corresponding signal produced by the amplimers for
the β-actin gene using the same cDNA specimen.
Measurement of CCL2 and CXCL10 Concentrations
Chemokines concentrations in A549 cell and primary cul-
tured AEC-II supernatants were measured in duplicate by
commercial available ELISA kits. Human CCL2 and
CXCL10 ELISA kits were from HyCult biotechnology
(Uden, the Netherlands). The assays were performed as
suggested by the suppliers. Optical density readings were
obtained with a MRX Microplate Reader and analyzed
with Revelation 2.0 software (both from Dynex Technol-
ogies, FRG). The lower detection limit of the assays was 10
pg/ml for CCL2 and 20 pg/ml for CXCL10. For duplicate
samples an intra assay coefficient of variation (CV) of <
10% and interassay CV of < 20% was accepted.
In Situ Hybridization (ISH)
Paraffin embedded lung tissue samples were prepared
from the same surgical specimens as described above and
used for ISH. These tissue samples showed normal archi-
tecture with few intra-alveolar macrophages and edema.
Some lung tissue explants were placed in CM alone or
with IFN-γ (500 U/ml) and IL-1β (500 U/ml), and/or 10-
4 M dexamethasone and incubated at 37°C in humidified
air containing 5% CO2 for 24 h. After incubation, these
lung tissue explants were further used for ISH. The cDNA
probes corresponding to CCL2 and CXCL10 mRNAs were
produced by PCR as described before, filtered through
Centri-Sep spin columns (Applied Biosystems, Foster
City, CA), and labeled with digoxigenin (DIG) following
the manufacturer's instructions (Dig-High-Prime, Roche,
FRG). After deparaffinization, in situ hybridization was
carried out overnight and, after washing at high strin-
gency, detection was performed by application of Anti-
Dig/alkaline-phosphatase-conjugate and new-fuchsin as
substrate for alkaline phosphatase [22]. Slides were coun-
Table 1: Primers used in RT-PCR analysis
cDNA Primer Sequence* Product Size (bp)
CCL2 F† : 5'-CAA ACT GAA GCT CGC ACT CTC GCC-3'
R† : 5'-ATT CTT GGG TTG TGG AGT GAG TGT TCA-3'
356
CXCL9 F: 5'-CGT GGT AAA ACA CTT GCG GAT ATT-3'
R: 5'-CAA TCA TGC TTC CAC TAA CCG ACT-3'
376
CXCL10 F: 5'-CCA TGA ATC AAA CTG CGA TTC TG-3'
R: 5'-CTT GGA AGC ACT GCA TCG ATT T-3'
338
CXCL11 F: 5'-AAA GGC TGG TTA CCA TCG GAG T-3'
R: 5'-RTGT TGC CAG TAT CCC ATA GCG T-3'
444
CD3 F: 5'-GGC TGT CCT CAT CCT GGC TAT CAT-3'
R: 5'-ACT GGT TTC CTT GAA GGT GGC TGT-3'
517
CD14 F: 5'-ACT CCC TCA ATC TGT CGT TCG CTG-3'
R: 5'-CTG AAG CCA AGG CAG TTT GAG TCC-3'
341
SP-A F: 5'-TCT TTG GAT GCC AAC TCA GC-3'
R: 5'-CTT TAT TCA GCT CAG GGG TG-3'
666
β-actin F: 5'-AGC GGG AAA TCG TGC GTG-3'
R: 5'-CAG GGT ACA TGG TGG TGCC-3'
309
*All primers were synthesized by MWG-Biotech (MWG-Biotech AG, Ebersberg, FRG); † F and R denote forward and reverse primer respectivelyRespiratory Research 2005, 6:75 http://respiratory-research.com/content/6/1/75
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terstained with Mayers hemalum and mounted with Kay-
ser's glyceringelatine. For negative control, sections were
hybridized with hybridization buffer in the absence of
labeled cDNA probes. Hybridization of a probe targeting
the mRNA of SP-A, a specific product of AEC-II, served as
an additional positive control.
Statistical Analysis
Data are expressed as means ± SEM. Statistical compari-
sons were made by ANOVA with post hoc Fisher's pro-
tected least significant difference (PLSD) for each agent
separately. Probability values were considered significant
if they were less than 0.05. All testing was done using
StatView 5.0 program (SAS Institute Inc., Cary, NC) for
Macintosh computers.
Results
Chemokine mRNA expression by A549 cells
In preliminary experiments, RT-PCR was performed on
the AEC-II-like cell line A549 to assess the spectrum of
chemokine mRNA expression at baseline and in response
to 24-h stimulation by TNF-α, IFN-γ, and IL-1β at different
concentrations. In the same experiments, we also investi-
gated the effects of the combinations of the above men-
tioned cytokines and different culture periods on
chemokine mRNA expression by A549 cells. A549 cells
spontaneously expressed mRNA for CCL2 (Figure 1A),
and there was a moderate enhancement within 24 h of
culture (Figure 1B). Stimulation with TNF-α, IFN-γ or IL-
1β resulted in modulation of the steady-state level of
CCL2 mRNA within 24 h, and at the end-time point of
cultures proinflammatory cytokines slightly increased
CCL2 mRNA expression level in a concentration-depend-
ent manner (Figure 1B). Although the differences of CCL2
mRNA accumulation in non-stimulated and TNF-α-, IFN-
γ-, or IL-1β-stimulated A549 cells were not obvious, prob-
ably due to the high baseline level of CCL2 expression,
stimulation with the combination of TNF-α, IFN-γ, and
IL-1β led to higher levels of CCL2 mRNA accumulation in
a time-dependent fashion (Figure 1B). In contrast,
CXCL10, CXCL11, and CXCL9 transcripts were not
detected in non-stimulated A549 cells. As shown in Figure
1, resting A549 cells, as well as TNF-α- or IL-1β-treated
cells, do not express detectable amounts of CXCL10 or
CXCL9 mRNA. Although no detectable amount of
CXCL11 transcripts was found in non-stimulated A549
cells, the stimulation with TNF-α, IL-1β or IFN-γ strongly
induced CXCL11 mRNA expression (Figure 1A and 1C).
IFN-γ alone induced mRNA expression of CXCL10, but
not CXCL9, in a dose- and time-dependent manner (Fig-
ure 1A and 1B). A considerable accumulation of CXCL10
and CXCL9 mRNA was observed in A549 cells stimulated
with IFN-γ plus, either IL-1β or TNF-α, with maximal
expression levels being reached by 16 h for CXCL9 and by
24 h for CXCL10, respectively (Figure 1A and 1B).
CXCL10, CXCL11, and CXCL9 transcripts were also
highly increased by stimulation with combinations of
IFN-γ, IL-1β, and TNF-α at different concentrations (Fig-
ure 1A and 1B). CXCL11 gene appears to be more sensi-
tive on cytokine mediated induction than CXCL10 and
CXCL9. The level of CXCL11 mRNA was increased within
8 h, and declined to baseline at 24 h in the presence of
TNF-α or IL-1β in a time- and dose-dependent manner.
IFN-γ clearly up-regulated the accumulation of CXCL11
mRNA at all concentrations tested (Figure 1C). Although
kinetics of CXCL10, CXCL11, and CXCL9 mRNA expres-
sion in IFN-γ-stimulated A549 cells differed greatly from
those of IFN-γ plus IL-1β plus TNF-α cells (as in the former
conditions, CXCL11 and CXCL10 transcripts reached a
maximum at 16 or 24 h, whereas in the latter relatively
high levels of chemokine mRNA were detected at 4 or 8
h), it is evident that IFN-γ represents the most potent stim-
ulus to induce mRNA expression of all three CXCR3 ago-
nistic chemokines and that IL-1β and TNF-α exaggerate
the up-regulatory effect of IFN-γ in A549 cell line (Figure
1B).
Chemokine mRNA Expression by AEC-II in Primary 
Culture
Next we examined the effects of proinflammatory
cytokines on the expression of chemokine genes expres-
sion by human AEC-II to determine whether a similar pat-
tern of mRNA expression and induction as in A549 cells is
also detectable in primary AEC-II. As experiments
employing A549 cells showed that chemokine mRNA
expression levels peaked 24 h after stimulation with
proinflammatory cytokines, we used this time point to
study the effect of different doses of TNF-α, IFN-γ, and IL-
1β on CCL2, CXCL10, CXCL11, and CXCL9 mRNA accu-
mulation in primary cultured AEC-II. We found that non-
cultured AEC-II expressed detectable amounts of CCL2
mRNA, which were significantly increased by culture with
or without cytokine stimulation (Figure 2, P < 0.01, n = 8).
TNF-α and IL-1β slightly increased CCL2 mRNA accumu-
lation in a dose-dependent fashion, but this was not sta-
tistically significant compared with non-stimulated cells
(Figure 2, P > 0.05, n = 8). The maximum level of CCL2
mRNA expression was seen in cells stimulated with 10 U/
ml of IFN-γ gradually decreasing to baseline values with
increasing of IFN-γ concentration (Figure 2).
The CXCL mRNA expression pattern of primary AEC-II
was similar to that of A549 cells, with some peculiarities
in cytokine-stimulated cells. As shown in Figure 3, neither
non-cultured nor non-stimulated AEC-II expressed detect-
able amount of CXCL9 mRNA in all experiments
performed. In contrast to A549, CXCL9 mRNA was
detected in AEC-II after TNF-α, IL-1β and, more strongly,
after IFN-γ treatment. CXCL11 and CXCL10 mRNA were
expressed in non-stimulated AEC-II after 4 h of culture,Respiratory Research 2005, 6:75 http://respiratory-research.com/content/6/1/75
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mRNA expression of CCL2 and CXCR3 agonistic chemokines by A549 cells Figure 1
mRNA expression of CCL2 and CXCR3 agonistic chemokines by A549 cells. A : Dose response of proinflammatory cytokine-
induced CCL2, CXCL10, CXCL11, and CXCL9 mRNA accumulation. The representative gel images from one out of three 
independent experiments are shown. Expression of β-actin in the same samples demonstrates equal loading of lanes. B : Den-
sitometric analysis of the CCL2, CXCL10, CXCL11, and CXCL9 mRNA expression. RT-PCR was performed with total RNA 
obtained from A549 cells stimulated for the indicated times with 50 U/ml IFN-γ (IFN50), 50 U/ml IFN-γ and 5 ng/ml TNF-α 
(IFN50+TNF5) or 50 U/ml IL-1β (IFN50+IL50), and a combination of cytokines (CTMX) 50 U/ml of IFN-γ and IL-1β, and 5 ng/
ml TNF-α. The mRNA-amplificates from each culture was quantitated individually. The distinct dots on the lines represent the 
mean percentages of β-actin density of duplicate determinations at each individual time-point for different concentrations/com-
binations of cytokines. Data are from one representative experiment out of three. C : Dose- and time-dependent effects of 
TNF-α, IFN-γ, and IL-1β at indicated concentrations on CXCL11 mRNA expression by A549 cells are shown.Respiratory Research 2005, 6:75 http://respiratory-research.com/content/6/1/75
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peaked at 16 h and slightly decreased thereafter (Figure 3
and not shown). However, both CXCL10 and CXCL11
were expressed at relatively higher levels after IL-1β, and
especially, after IFN-γ treatment in a dose-dependent
manner (Figure 3). We did not study the effects of differ-
ent cytokine combinations on the chemokine mRNA
expression patterns due to the strait in amounts of pure
human AEC-II isolated from lung tissue samples. No
changes in SP-A mRNA expression of non-stimulated or
cytokine-stimulated AEC-II were detected after 24 h cul-
tures (data not shown).
Production of CCL2 and CXCL10 by AEC-II in Primary 
Culture
Because CXCL10 mRNA was strongly up-regulated in
AEC-II after cytokine stimulation and CCL2 mRNA was
CCL2 mRNA expression by primary cultured AEC-II in response to proinflammatory cytokine stimulation for 24 h Figure 2
CCL2 mRNA expression by primary cultured AEC-II in response to proinflammatory cytokine stimulation for 24 h. Upper part 
of figure shows representative images of CCL2 mRNA amplificates in AEC-II derived from one of eight identical experiments. 
Expression of β-actin in the same samples demonstrates equal loading of lanes. Line 0 – 10 represent cells non-cultured, non-
stimulated and stimulated with TNF-α, IFN-γ, or IL-1β, respectively. Line M indicates the molecular weight marker. The lower 
part of figure shows the results of densitometric analysis of the CCL2 mRNA expression. The mRNA-amplificates from each 
culture were quantitated individually. Values presented are the mean percentages of β-actin density ± SEM calculated from 
eight independent experiments. *P < 0.05 compared with non-cultured cells.Respiratory Research 2005, 6:75 http://respiratory-research.com/content/6/1/75
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detected even in non-stimulated cells, we measured the
concentrations of these chemokines in supernatants of
AEC-II cultures in the presence or absence of proinflam-
matory cytokines. In accordance with mRNA expression
patterns of CCL2 and CXCL10, AEC-II spontaneously
release CCL2 at concentration of 12.7 ± 2.0 ng/ml/106
cells (Figure 4A), and no detectable amounts of CXCL10
were released by non-stimulated AEC-II after 24 h of cul-
tures (Figure 4B). As shown in Figure 4A, treatment of the
AEC-II with IL-1β caused a significant increase in the pro-
duction of CCL2 (10 U/ml of IL-1β: 25.5 ± 4.2; 50 U/ml:
24.4 ± 3.6; 100 U/ml: 23.8 ± 4.4 ng/mL/106 cells respec-
Effect of TNF-α, IFN-γ, and IL-1β stimulation at indicated concentrations on CXCL10, CXCL11, and CXCL9 mRNA expres- sion by primary cultured AEC-II Figure 3
Effect of TNF-α, IFN-γ, and IL-1β stimulation at indicated concentrations on CXCL10, CXCL11, and CXCL9 mRNA expres-
sion by primary cultured AEC-II. One representative image of eight independent experiments for each chemokine is shown in 
the upper part of figure. Expression of β-actin in the same samples demonstrates equal loading of lanes. Line 0 – 10 represent 
cells non-cultured, non-stimulated and stimulated with TNF-α, IFN-γ or IL-1β respectively. Line M indicates the molecular 
marker. The lower part of figure shows the results of densitometric analysis of CXCL10, CXCL11, and CXCL9 mRNA expres-
sion in AEC-II isolated from one individual. Each panel shows the mean values of duplicate assays for each condition from one 
experiment representative of eight.Respiratory Research 2005, 6:75 http://respiratory-research.com/content/6/1/75
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tively, P < 0.05, n = 12). TNF-α slightly increased the CCL2
release at concentrations of 1 ng/ml (18.4 ± 4.2 ng/ml/106
cells), 5 ng/ml (18.2 ± 3.8 ng/ml/106 cells) and 10 ng/ml
(19.2 ± 4.4 ng/ml/106 cells), however, this effect was sta-
tistically significant only for a TNF-α concentration of 10
ng/ml (P < 0.05; Figure 4A). However, IFN-γ did not sig-
nificantly change CCL2 protein levels in AEC-II cultures
compared with non-stimulated controls (Figure 4A). In
marked contrast, AEC-II generated ng/ml quantities of
CXCL10 upon stimulation with IFN-γ after 24 h, but TNF-
α and IL-1β exerted only marginal effects. As seen in Fig-
ure 4B, 10 U/ml of IFN-γ was sufficient to induce a signif-
icant increase in the CXCL10 generation by AEC-II being
maximal at 100 U/ml of cytokine. A TNF-α concentration
of 10 ng/ml slightly, but statistically significantly
increased CXCL10 generation by AEC-II compared with
non-stimulated controls (Figure 4B).
Since IL-1β and IFN-γ disclosed the highest differences in
the stimulatory capacity for CCL2 and CXCL10 releases in
24-h AEC-II cultures, the effects of both cytokines were
analyzed in more detail. As shown in Figure 5A, IL-1β
increased CCL2 release in a time- and dose-dependent
manner. The IL-1β-induced increase in CCL2 production
could be detected as early as 4 h after stimulation and sig-
nificantly increased with time (Figure 5A). Just within the
first 4 h of AEC-II cultures IFN-γ induced a modest CCL2
release, which did not differ statistically significantly from
controls. Conversely, with the increase of culture time
IFN-γ concentration-dependently decreased CCL2 release
of AEC-II in a non-significant magnitude (Figure 5A). The
dose- and time-dependent increases of IFN-γ and IL-1β on
CXCL10 generation are shown in Figure 5B. A clear-cut
dose- and time dependency as seen for stimulation with
IFN-γ could also be observed for IL-1β. The low CXCL10
background release increased significantly in the presence
of 50 or 100 U/ml IL-1β at time points 16 and 24 h. How-
ever, this increase is about 10-fold lower compared with
the CXCL10 levels induced by IFN-γ at the same concen-
trations and time points (Figure 5A and 5B). Experiments
with the cell line A549 demonstrated that non-stimulated
cells generate significantly lower levels of immunoreactive
CCL2 (P < 0.01; 2.3 ± 0.9 ng/ml/106 cells after 24 h, n =
6) compared with primary cultured AEC-II (data not
shown). Additionally, TNF-α, but not IFN-γ or IL-1β, up-
regulated CCL2 release, and this effect was only seen after
4 h of culture (data not shown). A549 cells also released
CXCL10, and consistent with the mRNA data, a combina-
tion of IFN-γ with IL-1β and/or TNF-α significantly up-
regulated CXCL10 release by these cells. IFN-γ/IL-1β/TNF-
α-stimulated A549 cells generated 5.3 ± 1.9 ng/ml/106
cells (n = 3) of CXCL10 protein for 24 h, which was a 50-
fold increase over IFN-γ-stimulated cells (data not
shown).
CCL2 and CXCL10 mRNA expression by AEC-II in vivo 
To determine if AEC-II expression of those chemokines
can also be regulated in vivo , we took advantage of an in
situ hybridization (ISH) method. ISH using DIG-labeled
cDNA probes detected specific signals for CCL2 mRNA
mainly in intra-alveolar macrophages in all lung tissue
preparations included in the present study. Positive sig-
nals for CCL2 mRNA were also detected in AEC-II, which
were typically localized at alveolar corners and exhibited
cuboidal morphology (Figure 6A, arrowheads). After
treatment with IL-1β almost all AEC-II displayed strong
positive signal for CCL2 mRNA (Figure 6C, arrowheads).
The same pattern of CCL2 mRNA expression was observed
in both macrophages located in the alveolar lumen and
those adjacent to alveolar epithelium (Figure 6C, inset,
arrows). Interestingly, a weak positive signal was also
detected in AEC type I (Figure 6C, sharp arrowheads).
Dexamethasone treatment markedly inhibited IL-1β-
induced CCL2 expression, but did not change basal levels
compared to non-stimulated (data not shown) or non-
cultured samples (Figure 6E and 6A). In contrast to CCL2,
no positive signals for CXCL10 mRNA were detected in
tissue explants from normal lungs (Figure 6B). However,
after stimulation of whole lung tissue explants for 24 h in
vitro with IL-1β and IFN-γ, in AEC-II (Figure 6D, inset,
arrowheads) as well as in AM clear positive signals for
CXCL10 mRNA could be detected (Figure 6D, arrows).
Treatment with dexamethasone almost completely sup-
pressed cytokine-induced CXCL10 mRNA in AEC-II and
AM (Figure 6F, arrows). In situ hybridization was also per-
formed on lung tissue preparations obtained from
patients with pulmonary sarcoidosis and tuberculosis.
The strong positive signals of CXCL10 mRNA were
observed in AM and AEC-II on the perifocal zones of sar-
coid granulomas (Figure 6G) and in the alveolar
epithelium on tuberculous lung tissue preparations (Fig-
ure 6H). The specific signals were not detected in control
preparations, in which specific DNA probes were substi-
tuted by hybridization buffer (not shown). For control
purposes SP-A mRNA predominantly localized in AEC-II
was detected in all lung tissue preparations (data not
shown).
Discussion
To increase our knowledge in mechanisms controlling the
recruitment and activation of inflammatory cells in the
alveolar space and the role of alveolar epithelial cells type
II in the cytokine network of the lung, we investigated the
effects of proinflammatory cytokines on chemokine gene
expression and production by human primary AEC-II. We
examined CCL2, a CC chemokine that attracts predomi-
nantly monocytes/macrophages and activated T cells by
binding to CCR2, and CXCL9, CXCL10, and CXCL11, T
cell-specific chemokines binding to CXCR3. In this work,
we demonstrate that CCL2 mRNA is present in freshly iso-Respiratory Research 2005, 6:75 http://respiratory-research.com/content/6/1/75
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(A ) CCL2 and (B ) CXCL10 immunoreactivity in AEC-II supernatants after TNF-α, IFN-γ, and IL-1β stimulation at indicated  concentrations for 24 h Figure 4
(A ) CCL2 and (B ) CXCL10 immunoreactivity in AEC-II supernatants after TNF-α, IFN-γ, and IL-1β stimulation at indicated 
concentrations for 24 h. Values presented are means ± SEM (n = 12). Statistically significant differences from non-stimulated 
cells assessed by ANOVA with PLSD separately for each cytokine are indicated by an asterisk (*P < 0.05).Respiratory Research 2005, 6:75 http://respiratory-research.com/content/6/1/75
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lated AEC-II and its level is significantly up-regulated dur-
ing culture. The proinflammatory cytokines IL-1β, TNF-α,
and IFN-γ increased the accumulation of CCL2 mRNA in
24 h cultured AEC-II in a dose-dependent manner, how-
ever these effects were not statistically significant com-
pared with non-stimulated cells. CCL2 mRNA patterns of
Time course of spontaneous and cytokine-induced (A ) CCL2 and (B ) CXCL10 production by primary cultured AEC-II Figure 5
Time course of spontaneous and cytokine-induced (A ) CCL2 and (B ) CXCL10 production by primary cultured AEC-II. IL-1β, 
but not IFN-γ increases CCL2 release, whereas both IL-1β and IFN-  increase CXCL10 release in a time- and dose-depend-
ent manner. The increase induced by IL-1β is about 10-fold lower compared with the CXCL10 levels induced by IFN-γ at the 
same concentrations and time points. The distinct dots on the lines represent means of triplicate determinations at each time-
point for different concentrations of cytokine. *P < 0.05 compared to spontaneously produced chemokine levels by AEC-II. 
Data are representative results from three independent experiments.

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Localization of CCL2 and CXCL10 mRNA in lung tissue explants non-cultured and cultured with IL-1β and IFN-γ, in the pres- ence or absence of 10-4 M dexamethasone (DEX) for 24 h Figure 6
Localization of CCL2 and CXCL10 mRNA in lung tissue explants non-cultured and cultured with IL-1β and IFN-γ, in the pres-
ence or absence of 10-4 M dexamethasone (DEX) for 24 h. CCL2 mRNA is constitutively produced in normal lung tissue by 
AEC-II (arrowheads) and AM (arrows) (A ), and stimulation with 500 U/ml of human recombinant IL-1β and IFN-γ (C , inset) 
significantly up-regulates CCL2 mRNA expression by these cells compared to non-cultured (A ) or 24-h cultured controls 
(data not shown). AEC-I also show weak positive signal for CCL2 mRNA (C , sharp arrowheads). DEX treatment leads to inhi-
bition of the IL-1β-induced CCL2 mRNA production in AEC-II (E and C ), but does not change the basal expression (E and A 
). Panels B , D , and F show the same lung tissue explants treated as indicated above and hybridized with a CXCL10 specific 
probe. Panel D (inset) illustrates a prominent inducible effect of cytokine-stimulation on CXCL10 mRNA expression in situ by 
AEC-II (arrowheads) and AM (arrows), and panel F depicts the inhibitory effect of DEX on IFN-γ/IL-1β-induced CXCL10 
mRNA expression. Data of one representative experiment from five are shown. Panels G and H illustrate CXCL10 mRNA 
localization in the lung from patients with pulmonary sarcoidosis and tuberculosis respectively. Control slides, in which hybrid-
ization buffer alone was applied, display no reactivity in all experiments (data not shown).Respiratory Research 2005, 6:75 http://respiratory-research.com/content/6/1/75
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resting and cytokine-stimulated A549 cells, which were
used as control, disclosed the same expression profiles as
observed in primary AEC-II. The highest CCL2 mRNA
level was detected in A549 cells stimulated with a
combination of IL-1β, TNF-α, and IFN-γ, and this effect
was time-dependent.
In agreement with mRNA data, we also found that signif-
icant amounts of CCL2 protein were spontaneously
secreted from primary cultured AEC-II, and IL-1β or TNF-
α, but not IFN-γ, up-regulated CCL2 production, confirm-
ing a previous study [8]. In contrast to studies of IFN-γ
effects on CCL2 release by human bronchial and endothe-
lial cells and fibroblasts we could not demonstrate that
IFN-γ up-regulates the CCL2 protein production by AEC-
II and A549 cells [23-25]. Although, IFN-γ modulates
CCL2 mRNA expression in AEC-II, time course experi-
ments showed that IFN-γ does not significantly influence
CCL2 release. These results are in line with other observa-
tions of IFN-γ being rather an inhibitor than promoter of
spontaneous and LPS-induced tissue-specific CCL2
releases [26,27]. Interestingly, IFN-γ also selectively inhib-
its the CCR2 expression on human monocytes [28]. It
seems that differences in IFN-γ regulation of CCL2 may
result from differential responses of target cells to pro- and
anti-inflammatory stimuli and to cell type-specific pat-
terns of stimulus sensitivity. In contrast to IFN-γ, IL-1β
was the most potent stimulus on CCL2 release by AEC-II.
More than 25 ng/ml/106 cells of CCL2 were detected in
supernatants collected from AEC-II, activated with IL-1β
for 24 h. This is the highest level reported to date for
cytokine-stimulated CCL2 secretion from airway
epithelial cells. In comparison, in a 24-h period, human
bronchial epithelial cells treated with IL-1β released 25-
fold less CCL2 [23], and in our experiments, A549 cells
maximally stimulated with TNF-α secreted 10-fold less
protein. Furthermore, Sadek and associates demonstrated
that human AM retrieved from BAL generate the same lev-
els of CCL2 after 72-h stimulation with LPS in culture
[29]. Thus, spontaneous CCL2 level produced by AEC-II is
of biological importance since on a per cell basis it is
three-fold higher than baseline CCL2 level generated by
human AM for 72 h in vitro [29]. Although we did not
determine the capacity of IL-1β-stimulated AEC-II to
attract mononuclear cells, previous studies have shown
that AEC-II-derived CCL2 is strongly chemotactic for
CD14+ and CD3+ cells in vitro and in vivo [8,10,15].
Under normal condition the alveolar space contains a low
number of leukocytes with AM forming about 95% of
total cell population. As AEC-II are uniquely positioned in
the borders between the microvascular compartment and
the alveolar space, and constitutively generate considera-
ble amounts of CCL2, one may hypothesize that this AEC-
II-derived chemokine is responsible, at least partially, for
basal recruitment of monocytes and their differentiation
into AM, in healthy humans. In this respect Gunn and col-
leagues have demonstrated that CCL2 overexpression in
the lung of transgenic mice leads to a marked increase in
the number of BAL monocytes, but does not cause inflam-
matory activation of cells [15]. According with our in vitro
and  in vivo results, it is necessary to have additional
inflammatory agonists such as macrophage-derived IL-1β
and/or TNF-α for increasing and amplifying CCL2 expres-
sion by AEC-II, which in turn might be important factors
for further development and manifestation of lung
inflammation.
In contrast to CCL2, we could demonstrate that IFN-γ
induces the expression of CXCL9, CXCL10, and CXCL11
by AEC-II. In fact, IFN-γ significantly up-regulated CXCL9,
CXCL10, and CXCL11 mRNA accumulation and CXCL10
production of AEC-II and A549 cells. Albeit at low levels,
CXCL10, CXCL11, and CXCL9 were also induced directly
by IL-1β and TNF-α in primary cultured AEC-II. Interest-
ingly, the kinetics of CXCL11 mRNA expression in IFN-γ-
or IFN-γ plus TNF-α and IL-1β-treated A549 cells were
faster than those of CXCL9 or CXCL10 mRNA expression.
Furthermore, the effect of TNF-α and IL-1β was more pro-
nounced on CXCL11 mRNA accumulation in A549 cells
compared with CXCL10 or CXCL9, suggesting that differ-
ent pathways might be involved in CXCL9 and CXCL10
expression at one side, and CXCL11 on the other side,
even though they are all induced by IFN-γ. The signifi-
cance of a sequential regulated expression of CXCL10,
CXCL11, and CXCL9 by AEC-II is only a matter of specu-
lation, but a similar pattern has been found in other cell
types, for instance, in endothelial cell, bronchial epithelial
cells, and neutrophils [30-32]. CXCL10 mRNA
accumulation in primary cultured AEC-II and in the con-
trol A549 cells closely reflected levels of secreted CXCL10
protein, as previously shown in human bronchial epithe-
lial cells [31], suggesting that the CXCL10 production is
strongly regulated and dependent on the transcriptional
mechanisms.
To date, a number of cellular sources of CCL2 and
CXCL10 in the inflamed lung have been identified,
including macrophages, fibroblasts, airway epithelium,
and endothelial cells. In the present study, we have evalu-
ated the ability of human AEC-II to express and produce
CCL2 and CXCL10 in vitro , and express CCL2 and
CXCL10 mRNA in situ . ISH studies revealed intense posi-
tive signals for CXCL10 mRNA in AEC-II, as well as in
interstitial and alveolar macrophages in lung tissue
explants after in vitro treatment with IL-1β and/or IFN-γ.
In contrast, no positive signal was detected in non-cul-
tured or cultured lung tissue explants with medium alone
or with IFN-γ/IL-1β and 10-4 M dexamethasone. On the
other hand, CCL2 mRNA expression was detected in AEC-Respiratory Research 2005, 6:75 http://respiratory-research.com/content/6/1/75
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II and AM in all lung tissue explants, and IL-1β, alone or
in combination with IFN-γ, markedly up-regulated CCL2
mRNA expression of AEC-II and AM in situ . Treatment
with dexamethasone attenuated the signal intensities in
cytokine-stimulated, but not in non-stimulated prepara-
tions. These results from in vitro stimulation and dexame-
thasone inhibition experiments demonstrated that AEC-II
were capable of expressing significant quantities of
CXCL10 mRNA in situ only under local IFN-γ or IL-1β acti-
vation, in contrast to CCL2, which is expressed constitu-
tively, and proinflammatory cytokines only up-
modulated the steady state mRNA levels of CCL2. These
data corroborate well observations from van der Velden et
al. and Witowski et al., which have shown that dexameth-
asone and actinomycin D strongly inhibit cytokine-driven
but not constitutive CCL2 release in human bronchial epi-
thelium and peritoneal fibroblasts [23,33].
Our in situ hybridization data are consistent with observa-
tions from Jaffe and associates, and Martin et al., which
have shown that only after local, but not after systemic
administration of recombinant human IFN-γ in healthy
volunteers, CXCL10 mRNA was induced in AM [34,35].
Moreover, production of CXCL10 and CXCL9 in the
injured lung was not completely suppressed in mice defi-
cient for IFN-γ or the IFN-γ receptor [36], and CXCL10,
but not CCL2, failed in the human T cell transendothelial
migration model [37]. All these data suggest that in con-
trast to CCL2, CXCL10 is directly induced by IFN-γ
released from cells within the lung rather than by IFN-γ
derived from distant sites, and that alternate agonists are
present in the alveolar compartment, which may together
with IFN-γ or separately amplify CXCL10 expression, and
subsequently promote local accumulation of CXCR3+
cells in the alveolar space. In addition, ISH data strongly
suggest that effects of the proinflammatory cytokines on
CCL2 and CXCL10 mRNA accumulation and protein gen-
eration in primary cultured AEC-II were not due to arti-
facts elicited by cell isolation procedure or culture
conditions.
The quantitative differences, time and cytokine-inducing
profile dependencies in CCL2, CXCL9, CXCL10, and
CXCL11 expression of AEC-II suggest that there are several
cytokine/chemokine cascades within the injured lung,
which in turn, determine the flexible programs of recruit-
ment and activation of inflammatory cells into the alveo-
lar space. For instance, alveolar macrophage-derived pro-
inflammatory cytokines such as IL-1 and TNF-α, but not
IFN-γ, directly up-regulate expression by AEC-II of certain
chemokines including CCL2 and CXCL8 [8,10,19,38]. In
our previous report we demonstrated that in close similar-
ity with CCL2, TNF-α and IL-1β, but not IFN-γ, up-modu-
lated constitutive interleukin-8/IL-8 (CXCL8) release in
primary cultured AEC-II, and cytokine-derived increase of
CXCL8 basal level was only two-fold lower than LPS-
induced CXCL8 release in AM [19]. Our results demon-
strating high levels of CCL2, CXCL8 and CXCL10
production by AEC-II in vitro indicate that AEC-II have the
potential to participate in physiologic and pathologic
macrophage, neutrophil and T cell responses within the
alveolar space. By chemoattracting IL-1-producing mono-
cytes/macrophages, TNF-α-producing neutrophils and
IFN-γ-producing CD4+ or CD8+ cells in close proximity to
the epithelium, AEC-II-derived CCL2, CXCL8, CXCL9,
CXCL10, and CXCL11, which themselves are up-regulated
by IL-1β and/or TNF-α, and IFN-γ, may activate several
positive feedback loops. In addition, it has been reported
that CXCL10 selectively activated and enhanced antigen-
driven IFN-γ gene expression in T cells [39]. Thus, it is
tempting to speculate that locally produced CCL2 and
CXCL10 by AEC-II attract activated memory T cells into
alveoli and further amplify antigen-driven IFN-γ response
of Th1 cells. The strong confirmation of this hypothesis
results from animal models of the lung inflammation and
some clinical observations in pulmonary diseases. It has
been demonstrated that bronchoalveolar lavage (BAL)
cells disclosed the Th1-dominated pattern in transgenic
rats that express CXCL10 in the lung, and BAL lym-
phocytes of HIV-infected patients with T-cell alveolitis
were CD8+ T cells expressing high levels of CXCR3 and
IFN-γ, which exhibited a high migratory capability in
response to CXCL10 and CXCL9 [40,41]. Similarly, over-
expression of human CCL2 in transgenic AEC-II or intra-
tracheal administration of murine MCP-1 caused a sub-
stantial accumulation of activated monocytes within the
bronchoalveolar space of mice [15,16]. Additionally,
Miotto et al. reported that CXCL10 expression was
strongly up-regulated in Th1-mediated lung diseases,
whereas increased CCL2 expression was not specifically
associated with Th1 or Th2 patterns[3]. Our in situ hybrid-
ization data confirm that in contrast with normal lung tis-
sue preparations a strong expression of CXCL10 can be
detected in sarcoidosis and tuberculosis – diseases in
which the Th1-type cytokine IFN-γ is up-regulated.
Beside the pro-inflammatory effects of CXCL9, CXCL10,
and CXCL11 they also exhibit down-regulation e.g. on the
migration of eosinophils [42] or on angiogenesis [43].
This is of interest, because it could be shown in a mouse
model that CXCL11 attenuates fibrosis by inhibition of
vascular remodeling [44]. In addition, it could be demon-
strated that CXCL9 down-regulates IL-4 expression but
up-regulates IFNγ expression by T cells. This illustrates
that AEC-II not only induce the migration of Th1 cells by
the release of CXCR3-ligands but they also participate in T
cell activation [20] and Th1 polarization of lung T cells.
Since it is known that AEC-II also express CXCR3A and
CXCR3B [45] it is tempting to speculate about a possibleRespiratory Research 2005, 6:75 http://respiratory-research.com/content/6/1/75
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Alveolar epithelial cells type II drive a leukocyte trafficking in host defense and specific immune response Figure 7
Alveolar epithelial cells type II drive a leukocyte trafficking in host defense and specific immune response. The schematic draw-
ing shows spatial distribution of chemokine expression and leukocyte recruitment: in healthy condition (A ) two chemokines, 
MCP-1/CCL2 and IL-8/CXCL8, are expressed constitutively by AEC-II and provided the physiological influx of monocytes 
(Mn), neutrophils (PMN), and lymphocytes (Ly) into alveolar space from pulmonary vasculature (VSL); in the initial phase of 
alveolar inflammation caused by inflammatory agents (B ) increasing alveolar macrophage (AM) and particularly epithelial 
expression of CCL2 and CXCL8 as well as the expression of CXCL10 and CXCL11 is paralleled by pronounced recruitment 
of Mn, PMN, and Ly to the alveolar compartment; further development of the immune response (C ) leads to the expression 
of high levels of CXCL9, CXCL10, and CXCL11 in AEC-II induced by IFN-γ and/or TNF-α, and IL-1β and associated with 
recruitment of activated T cells (Th1) to the interstitium and alveolar space. Mn and PMN reside in the interstitium and vascu-
lar compartment, which may be because of an IFN-γ inhibition of CCL2 and CXCL8 expression by AEC-II.Respiratory Research 2005, 6:75 http://respiratory-research.com/content/6/1/75
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activity of CXCL9, CXCL10, and CXCL11 on AEC-II in an
autocrine fashion, e.g. in re-epithelialization after lung
injury. Therefore, induction of CXCR3 agonists may in
some respects of benefit and may represent a possible
therapeutic mechanism of IFNγ therapy of IPF patients
[46].
Conclusion
Taken together our data indicate that although AEC-II
constitute about 15% of all lung cells, they may play a
prominent role in the pathogenesis of inflammatory lung
diseases. This study suggests that in human AEC-II,
CXCR3 agonistic chemokines are expressed and regulated
differently from CCL2. This pattern of differential expres-
sion and regulation was also seen when we explored the
effect proinflammatory cytokines on the IL-8/CXCL8
expression by human AEC-II [19]. We proposed that
CXCL8 and CCL2 constitutively produced by AEC-II may
mediate the „steady state" recruitment of blood cells, i.e.
monocytes/macrophages and neutrophils, which provide
a first line of the host defense in the lung (Figure 7A). Bac-
teria, endotoxin, viruses, and other pathogens may
enhance the production of CXCL8 and CCL2 by AEC-II
directly or with monocyte/macrophage derived TNF-α
and IL-1β as an intermediary. Cytokine-mediated
increases of CCL2 or CXCL8 levels may therefore be con-
sidered as an alert signal for leukocytes in the pulmonary
vascular bed and alveolar space (Figure 7B). The increased
numbers of leukocytes, including activated T cells, and the
presence of specific antigen can further elicit the develop-
ment of specific immune response within alveoli. Subse-
quently, activated T cells (Th1) released high amounts of
IFN-γ resulting in additional CXCL9, CXCL10, or CXCL11
induction by resident cells (AEC-II) of the alveoli. This
positive feedback loop establishes a new chemotactic gra-
dient inducing an increased migration of CXCR3+ T cells
from the blood stream through the endothelium into
both the interstitium and alveolar space (Figure 7C).
Under certain pathologic circumstances, several auto-reg-
ulatory loops involving alveolar epithelium might be
exaggerated, and may contribute to acute and chronic
inflammatory injuries of the lung.
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